BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28961693)

  • 1. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.
    Hosomi S; Yamagami H; Itani S; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    J Crohns Colitis; 2018 Jan; 12(1):87-95. PubMed ID: 28961693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study.
    Mavropoulou E; Mechie NC; Knoop R; Petzold G; Ellenrieder V; Kunsch S; Pilavakis Y; Amanzada A
    PLoS One; 2020; 15(5):e0233811. PubMed ID: 32470973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
    Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
    J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
    Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
    [No Abstract]   [Full Text] [Related]  

  • 11. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.
    Lakatos PL; Kiss LS; Palatka K; Altorjay I; Antal-Szalmas P; Palyu E; Udvardy M; Molnar T; Farkas K; Veres G; Harsfalvi J; Papp J; Papp M
    Inflamm Bowel Dis; 2011 Mar; 17(3):767-77. PubMed ID: 20865702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis.
    Yaegashi Y; Shirakawa K; Sato N; Suzuki Y; Kojika M; Imai S; Takahashi G; Miyata M; Furusako S; Endo S
    J Infect Chemother; 2005 Oct; 11(5):234-8. PubMed ID: 16258819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
    Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.
    Huang J; Lu J; Jiang F; Song T
    BMC Gastroenterol; 2023 Nov; 23(1):393. PubMed ID: 37964205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
    Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
    Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
    Boon GJ; Day AS; Mulder CJ; Gearry RB
    World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.